Calcium channel blockers (versus unexposed)

Low Apgar score (< 7) (at 5 min)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13875
R54259		 Darcie - Isradipine, 2004 Apgar score (fifth minute) < 7 late pregnancy prospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 0.35 [0.01;18.56] C 0/39   0/14 0 39
ref
Total 1 studies 0.35 [0.01;18.56] 0 39
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Darcie - Isradipine, 2004Darcie - Isradipine, 2004 0.35[0.01; 18.56]0390%ROB confusion: seriousROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.35[0.01; 18.56]-39 -NADarcie - Isradipine, 2004 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.35[0.01; 18.56]-39 -NADarcie - Isradipine, 2004 1 Tags Adjustment   - No  - No 0.35[0.01; 18.56]-39 -NADarcie - Isradipine, 2004 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 0.35[0.01; 18.56]-39 -NADarcie - Isradipine, 2004 1 All studiesAll studies 0.35[0.01; 18.56]-39 -NADarcie - Isradipine, 2004 10.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale0.35[0.01; 18.56]-39 -NADarcie - Isradipine, 2004 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Firoz (Nifedipine) (Apgar score <7 at 5 min ( ...Firoz (Nifedipine) (Apgar score <7 at 5 min (versus hydralazine iv)) 1.02[0.50; 2.05]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (Low Apgar score at 5 min) 2.08[0.40; 11.10]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT2 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (DUPLICATE) (Low Apgar score at 5 min) 2.08[0.40; 11.10]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT2 Shi (Nifedipine) - GESTATIONAL HYPERTENSION ( ...Shi (Nifedipine) - GESTATIONAL HYPERTENSION (Neonate 5-min Apgar score < 7 (versus intravenous labetalol)) 2.07[0.40; 10.65]0%-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT2 metaPregmetaPreg Out of scale0.35[0.01; 18.56]NaN%39----Darcie - Isradipine, 2004 10.510.01.0